Changes in proliferation and nuclear accumulation of β-catenin are associated with activating KRAS mutations in the presence of additional inactivating mutations in p53 and SMAD Family Member 4 (SMAD4), which promote the progression of adenoma to CRC. This evidence concerns the gene TP53 and colorectal carcinoma.